-

Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, MD, will participate in a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 1:30 p.m. PT (4:30 p.m. ET).

A live webcast and audio archive of the event will be available on the Investor Relations page of the Bausch + Lomb website: http://ir.bausch.com/investors/events-presentations.

About Bausch + Lomb
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

© 2026 Bausch + Lomb.

Contacts

Media Contact:
Chris Clark
chris.clark@bausch.com
(848) 360-1100

Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)

Bausch + Lomb Corporation

NYSE:BLCO

Release Versions

Contacts

Media Contact:
Chris Clark
chris.clark@bausch.com
(848) 360-1100

Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)

More News From Bausch + Lomb Corporation

Bausch + Lomb Launches R&D “Teach-in” Webinar Series

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D “Teach-in” webinar series that will provide deeper insights on the company’s differentiated product pipeline, which was unveiled in November 2025. On Monday, March 23, 2026, at 1:30 p.m. ET, Executive Vice President of Research & Development and Chief Medical Officer Yehia Hasha...

Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced today that Ophthalmology and Therapy published a new global narrative review examining the causes, burden and management of noninfectious conjunctival hyperemia (ocular redness). The review highlights the growing global prevalence of ocular redness driven by digital lifestyles, dry eye, contact lens wear, allergies an...

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2025 financial results. “We didn’t just grow in the fourth quarter – we grew smarter,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Meaningful EBITDA margin expansion and operating leverage is a clear sign of our commitment to financial excellence, and we plan to harnes...
Back to Newsroom